Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vortex Biosciences Takes On Board Becton Dickinson Alumnus

Executive Summary

Net Scientific's portfolio company and circulating tumor cell capture specialist Vortex Biosciences adds to its board of directors Deborah Neff, ex-chief operating officer of Complete Genomics and a former BD executive.

You may also be interested in...



DEVICE DEBUTS: Product And New Indication Launches From Medtronic, Strkyer, Siemens, And More

This month's edition of Device Debuts includes new product launches from Medtronic, Cochlear, Qualcomm, Titan Spine, Stryker, Philips, Nuance, Nevro, Siemens, Vortex BioSciences, ResMed, Respircardia, and others.

Device Debuts: Medtronic, Boston Scientific, Philips, Seventh Sense, Vortex, 410 Medical

Device Debuts is a new regular feature highlighting Medtech Insight editors’ top picks of medical devices that have been commercialized for the first time in the last month. This edition features an innovative minimally invasive surgical stapler, a pain-free blood-collection device, a novel approach for collecting, and circulating tumor cells, a rapid fluid-infusion device for critically ill patients, and an EP-mapping and navigation system.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel